GlassScriptPhysician profile
April Calvert
NPI 1609389436
$2,165.50
in general payments reported to CMS, 2019-2025
31 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $430 · 2023: $290 · 2024: $824 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.91 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $565.50 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Tandem Diabetes Care, INC. | $299.89 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $236.35 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Bayer Healthcare Pharmaceuticals INC. | $176.89 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $97.10 | 2024-2025 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.37 | 2022-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $68.48 | 2022-2023 | |
| Pfizer INC. | $57.74 | 2023-2024 | |
| Chiesi USA, INC. | $56.08 | 2024-2025 | Mycapssa |
| Novo Nordisk INC | $53.38 | 2021-2024 | Rybelsus, Ozempic |
| Janssen Biotech, INC. | $45.82 | 2021-2023 | Darzalex, Tecvayli |
| Xeris Pharmaceuticals, INC. | $41.98 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $40.37 | 2024-2025 | Korlym |
| Dexcom, INC. | $38.84 | 2021 | |
| Sequel Med Tech, LLC | $33.38 | 2025 | Twiist |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.36 | 2022-2025 | Trintellix |
| Insulet Corporation | $29.63 | 2023-2025 | Omnipod |
| Abbvie INC. | $23.43 | 2024 | |
| Merck Sharp & Dohme LLC | $20.26 | 2023 | Steglujan, Belsomra |
| Radius Health, INC. | $18.36 | 2023 | Tymlos |
| Amgen INC. | $18.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.97 | 2022 | |
| Recordati_rare_diseases_inc. | $15.86 | 2025 | Isturisa |
| Sobi, INC | $15.44 | 2025 | |
| Boston Scientific Corporation | $15.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.92 | 2023 | Quviviq |
| Averitas Pharma INC. | $14.59 | 2023 | Qutenza |
| Amarin Pharma, INC. | $13.08 | 2023 | |
| Amneal Pharmaceuticals LLC | $13.04 | 2022 | |
| Ibsa Pharma INC. | $12.38 | 2022 | |
| Medtronic, INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Calvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.